Novartis AG’s Kisqali lowers the risk of breast cancer recurrence in postmenopausal women with HR-positive, HER2-negative metastatic breast cancer, according to results from a trial. The trial, called MONALEESA-7, showed that Kisqali in combination with letrozole reduced the risk of recurrence or death by 51% compared to letrozole alone.
